Trial · NCT03107793
Participant flow55
How many started, completed or left each group, period by period.
1 to 20 of 55
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Induction Period (16 Weeks) | STARTED | Induction Period: Ustekinumab (6 Milligrams [mg]/Kilogram [kg]) | 498 | |
| Induction Period (16 Weeks) | STARTED | Maintenance Period: Treat to Target | 0 | |
| Induction Period (16 Weeks) | STARTED | Maintenance Period: Routine Care | 0 | |
| Induction Period (16 Weeks) | STARTED | Extension Period: Treat to Target | 0 | |
| Induction Period (16 Weeks) | STARTED | Extension Period: Routine Care | 0 | |
| Induction Period (16 Weeks) | Participants Who Entered the Maintenance Period | Induction Period: Ustekinumab (6 Milligrams [mg]/Kilogram [kg]) | 0 | |
| Induction Period (16 Weeks) | Participants Who Entered the Maintenance Period | Maintenance Period: Treat to Target | 219 | |
| Induction Period (16 Weeks) | Participants Who Entered the Maintenance Period | Maintenance Period: Routine Care | 221 | |
| Induction Period (16 Weeks) | Participants Who Entered the Maintenance Period | Extension Period: Treat to Target | 0 | |
| Induction Period (16 Weeks) | Participants Who Entered the Maintenance Period | Extension Period: Routine Care | 0 | |
| Induction Period (16 Weeks) | Participants Who Entered the Extension Period | Induction Period: Ustekinumab (6 Milligrams [mg]/Kilogram [kg]) | 0 | |
| Induction Period (16 Weeks) | Participants Who Entered the Extension Period | Maintenance Period: Treat to Target | 0 | |
| Induction Period (16 Weeks) | Participants Who Entered the Extension Period | Maintenance Period: Routine Care | 0 | |
| Induction Period (16 Weeks) | Participants Who Entered the Extension Period | Extension Period: Treat to Target | 147 | |
| Induction Period (16 Weeks) | Participants Who Entered the Extension Period | Extension Period: Routine Care | 176 | |
| Induction Period (16 Weeks) | COMPLETED | Induction Period: Ustekinumab (6 Milligrams [mg]/Kilogram [kg]) | 488 | |
| Induction Period (16 Weeks) | COMPLETED | Maintenance Period: Treat to Target | 0 | |
| Induction Period (16 Weeks) | COMPLETED | Maintenance Period: Routine Care | 0 | |
| Induction Period (16 Weeks) | COMPLETED | Extension Period: Treat to Target | 0 | |
| Induction Period (16 Weeks) | COMPLETED | Extension Period: Routine Care | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03107793/flow